Lenacapavir is an MPP priority since 2022. Its new mechanism of action and its long-acting properties (up to 6 months dosing interval) will likely make it an important product in HIV prevention and/or treatment (in combination with other medicines). The clinical programs continue to indicate favourable efficacy and safety profiles. Furthermore, lenacapavir has been prioritised by WHO in both PADO-5 and CADO-41.

1 Priorities for antiretroviral drug optimization in adults and children report of a CADO, PADO and HIVResNet joint meeting (accessible here).